|
|
|
July 30, 2008
CVRx Announces $84 Million Series E Financing
CVRx harnesses a well-understood biological reflex for the treatment of two of the most significant unmet needs in clinical medicine today: hypertension and congestive heart failure. The company has pioneered a device/electrode combination to stimulate the carotid sinus, triggering a reduction in blood pressure, even in patients who display high resistance to existing blood pressure medicines. CVRx recently completed an $84 million Series E Financing. Read more here.
--------------------------------
Back to News
|
|
| |
